Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06841354 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 61 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites revised (281)
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Study sites: 280 to 281 · Eligibility criteria expanded, about 24 words · Secondary endpoints: details revised at 8 of 11 entries Show 3 more changesShow less
    • Study sites: 280 to 281
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 8 of 11 entries
  3. Trial sites expanded: 274 → 280 locationsv59
  4. Trial sites expanded: 271 → 274 locationsv58
  5. Study sites: 270 to 271v57
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 268 to 270v56
  2. Site details revised at 2 of 268 sitesv55
  3. Study sites: 267 to 268v54
  4. Study sites revised (267)v53 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 266 to 267v52
  6. Study sites: 264 to 266v51
  7. Study sites: 263 to 264v50
  8. Study sites: 261 to 263v49
  9. Study sites revised (261)v48 See this version in full on ClinicalTrials.gov ↗
  10. Site details revised at 1 of 261 sitesv47
  11. Study sites: 260 to 261v46
  12. Study sites: 258 to 260v45
  13. Study sites: 257 to 258 Eligibility criteria expanded, about 15 wordsv44 Show 1 more changeShow less
    • Eligibility criteria expanded, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  14. Study sites: 255 to 257v43
  15. Study sites: 254 to 255v42
  16. Re-verified, no change to tracked fieldsv41
  17. Study sites: 253 to 254v40
  18. Study sites: 250 to 253v39
  19. Study sites: 248 to 250v38
  20. Study sites: 246 to 248v37
  21. Study sites: 243 to 246v36
  22. Study sites: 242 to 243v35
  23. Re-verified, no change to tracked fieldsv34
  24. Study sites: 238 to 242v33
  25. Study sites: 235 to 238v32
  26. Study sites: 232 to 235v31
  27. Study sites: 231 to 232v30
  28. Study sites: 228 to 231v29
  29. Study sites: 217 to 228v28
  30. Study sites: 211 to 217v27
  31. Study sites: 207 to 211v26
  32. Study sites: 203 to 207v25
  33. Study sites: 190 to 203v24
  34. Study sites: 183 to 190v23
  35. Study sites: 177 to 183v22
  36. Study sites: 173 to 177v21
  37. Study sites: 165 to 173v20
  38. Study sites: 160 to 165v19
  39. Study sites: 149 to 160v18
  40. Study sites: 144 to 149v17
  41. Study sites: 124 to 144v16
  42. Study sites: 94 to 124v15
  43. Study sites: 80 to 94v14
  44. Study sites: 70 to 80v13
  45. Study sites: 54 to 70v12
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Trial Details
NCT Number NCT06841354
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Triple Negative Breast Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov